Brilliant Violet 711™ anti-mouse Ly-6C Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

L3 cloned CTL cells

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone HK1.4 does not block the binding of clone RB6-8C5⁸.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells^1-3 and immunohistochemistry of frozen sections⁴.

Application References

(PubMed link indicates BioLegend citation)

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed

Product Citations

1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
2. Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed
3. Jeon Y, et al. 2022. Cancers (Basel). 14:. PubMed
4. Yashchenko A, et al. 2023. Front Immunol. 14:1082078. PubMed
5. Cansever D, et al. 2023. Nat Immunol. . PubMed
6. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
7. Chen G, et al. 2021. J Mol Cell Cardiol. 159:62. PubMed
8. Atalis A, et al. 2022. J Control Release. 347:476. PubMed
9. Manda-Handzlik A, et al. 2022. Int J Mol Sci. 23: . PubMed
10. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
11. García-García A, et al. 2023. Bioact Mater. 24:174. PubMed
12. Peng Y, et al. 2023. Respir Res. 24:33. PubMed
13. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
14. Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed
15. Hagan N, et al. 2020. Cell Death Dis. 1.086111111. PubMed
16. Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed
17. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
18. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
19. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
20. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
21. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
22. Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed
23. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
24. Bhattacherjee A, et al. 2021. Mol Neurodegener. 16:19. PubMed
25. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
26. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
27. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
28. Liang Z, et al. 2020. Pain. 161:2089. PubMed
29. Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed
30. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
31. Goldman E, et al. 2021. Cells. 10:. PubMed
32. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
33. Salvioni A et al. 2019. Cell Rep. 27(11):3254-3268 . PubMed
34. Guo P, et al. 2021. J Immunol. 207:408. PubMed
35. Koivisto CS, et al. 2020. Neoplasia. 1.252777778. PubMed
36. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
37. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
38. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
39. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
40. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
41. Van Winkle JA et al. 2018. Cell host & microbe. 24(5):665-676 . PubMed
42. Krueger A, et al. 2022. Front Microbiol. 12:789042. PubMed
43. Beura LK, et al. 2018. Immunity. 48:327. PubMed
44. Kar S, Colino J, Snapper C 2016. J Immunol. 196: 4204 - 4213. PubMed
45. Tummers B, et al. 2020. Immunity. 52(6):994-1006.e8. PubMed
46. Chitu V, et al. 2020. Cell Reports. 30(9):3004-3019. PubMed
47. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
48. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
49. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
50. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
51. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
52. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
53. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
54. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
55. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
56. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
57. Zhang L, et al. 2020. Cell. 442:181. PubMed
58. O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed
59. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
60. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
61. Ichinose M, et al. 2021. Sci Rep. 7200:11. PubMed

RRID

AB_2562630 (BioLegend Cat. No. 128037)

Antigen Details

Structure

14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.

Distribution

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8⁺ T cells.

Cell Type

Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.

Gene ID

17067 View all products for this Gene ID

UniProt

View information about Ly-6C on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats